Insider trade

Amgen (AMGN): SVP & CCO exercised options on 1,639 shares

Nancy A. Grygiel, SVP & CCO at Amgen, reported an option exercise of 1,639 shares.

1,639
Shares · @ $162.60
Traded
Nov 20, 2025
Filed
Nov 22, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 23, 2024CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  2. Nov 19, 2024CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  3. Sep 4, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  4. Sep 11, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  5. Sep 25, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  6. Oct 24, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  7. Nov 4, 2025Company filing · Form 8-K · ResultsReported its results
  8. Nov 12, 2025Insider · 2 peopleInsiders: 2 sales (~$2.6M)
  9. Nov 19, 2025FDAFDA drug approval: Imdelltra
  10. Nov 20, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)

What came next

  1. Dec 3, 2025Congress · 1 personMembers of Congress: 2 sales
  2. Jan 16, 2026CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  3. Jan 29, 2026CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  4. Jan 30, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
  5. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
  6. Feb 17, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  7. Feb 19, 2026InsiderOfficer sold ~$376K of AMGN shares in the open market
  8. Feb 26, 2026Insider · 1 personInsiders: 2 sales (~$20.8M)
  9. Feb 26, 2026CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  10. Mar 9, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  11. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Amgen

For Amgen, OQRO holds 6 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AMGN page.

Other recent filings by Nancy A. Grygiel, SVP & CCO

The full history of Nancy A. Grygiel, SVP & CCO is on the profile page.

How this filing works

Explore the data

Common questions

Which Amgen (AMGN) insider traded, and how much?

Nancy A. Grygiel, SVP & CCO at Amgen, reported an option exercise of 1,639 shares. At $162.60.

When did it happen, and when was it made public?

Traded: Nov 20, 2025. Filed: Nov 22, 2025. That is 2 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Amgen recently?

For Amgen, OQRO holds 6 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the AMGN page.

Does this mean AMGN stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Amgen

Everything OQRO holds on this company is on its AMGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data